ENTX news

Entera M.D. appoints Dr. Riccardo Camisasca, a veteran pharmaceutical executive, to lead its upcoming Phase 3 trial of the oral osteoporosis treatment EB613. Appointment underscores management focus on late-stage clinical development.

Entera Bio Ltd. announced positive FDA feedback for a Phase 3 osteoporosis study and a $275 million private placement, fortifying the company's financial ability to advance core assets.

Entrada shared a corporate presentation on its ENTR-601-44 candidate in Duchenne muscular dystrophy, outlining expectations for open-label period completion by end-2026 and multiple dose cohorts with escalating exposure. The presentation contains forward-looking statements about dystrophin restorati…